Revolution’s RAS Plans Move Ahead Despite Investors’ Safety Doubts

Tolerability problems with a high dose of its multi-RAS inhibitor in NSCLC patients knocked shares, but Revolution is pressing on in this setting and in pancreatic cancer. It also has eye-catching early results in colorectal cancer.